A new paper reports that Paxlovid-resistant Covid has been isolated, calling into question the utility of the drug as well as how it should be used. Is this cause for alarm? Not yet, but it could become just that. A look at viral resistance to drugs.
main protease
A Boston Globe article describes COVID-19 patients completing a course of Paxlovid – and then becoming ill again shortly thereafter. Is there something wrong with the drug? Is this something to worry about?
It was pretty much a forgone conclusion, but the FDA's decision to grant an Emergency Use Authorization to Pfizer's COVID drug, Paxlovid, could mark the turning point in our battle against the virus. Here's the story that you won't find anywhere in the press.
Pfizer's Paxlovid looks very promising in fighting COVID. It also provides a good opportunity to learn about how enzyme inhibitors work. For masochists only.
We're almost two years into the pandemic and there have been more than enough ups and downs to last a lifetime. But now we have a potentially big "up," because the results just came in on Pfizer's COVID drug Paxlovid—and they are nothing short of amazing. Will we finally be free of the terror of this pandemic? Maybe.
Antiviral drug development for COVID-19 took a back seat to vaccines during the brief time – when we thought that ending the pandemic was simply a matter of getting enough needles in enough arms. But the virus had other ideas: variants. Now it's looking like we may need a drug to complement the vaccines. Three are in development. Here's a look at Pfizer's PF-07321332. It should work, but don't hold me to that.